Evaluation of hepatic contrast enhancement with a hepatocyte-specific magnetic resonance imaging contrast agent (gadoxetic acid) in healthy dogs

Alexandra K. Bratton Department of Clinical Studies, Ontario Veterinary College, University of Guelph, Guelph, ON, N1G 2W1, Canada.

Search for other papers by Alexandra K. Bratton in
Current site
Google Scholar
PubMed
Close
 DVM
,
Stephanie G. Nykamp Department of Clinical Studies, Ontario Veterinary College, University of Guelph, Guelph, ON, N1G 2W1, Canada.

Search for other papers by Stephanie G. Nykamp in
Current site
Google Scholar
PubMed
Close
 DVM
,
Thomas W. G. Gibson Department of Clinical Studies, Ontario Veterinary College, University of Guelph, Guelph, ON, N1G 2W1, Canada.

Search for other papers by Thomas W. G. Gibson in
Current site
Google Scholar
PubMed
Close
 DVM, DVSc
,
Robert Cruz-Arámbulo Antech Diagnostic Imaging Canada Ltd, 6625 Kitimat Rd, Mississauga, ON L5N 6J1, Canada.

Search for other papers by Robert Cruz-Arámbulo in
Current site
Google Scholar
PubMed
Close
 DVM, MSc
, and
Stephen A. Kruth Department of Clinical Studies, Ontario Veterinary College, University of Guelph, Guelph, ON, N1G 2W1, Canada.

Search for other papers by Stephen A. Kruth in
Current site
Google Scholar
PubMed
Close
 DVM

Abstract

OBJECTIVE To determine, by means of MRI, the time to maximal contrast enhancement in T1-weighted images following IV administration of gadoxetic acid in healthy dogs and assess the impact of gadoxetic acid on the signal intensity of T2-weighted images.

ANIMALS 7 healthy dogs.

PROCEDURES No hepatic abnormalities were detected during ultrasonographic examination. Each dog was anesthetized and positioned in dorsal recumbency for MRI. Transverse T1- and T2-weighted images of the liver were acquired prior to and following (at 5-minute intervals) IV injection of 0.1 mL of gadoxetic acid/kg. Signal intensity of the liver parenchyma was measured in 3 regions of interest in the T1- and T2-weighted images before and at various times point after contrast agent administration. Time versus signal-to-noise ratio curves were plotted to determine time to maximal contrast enhancement and contrast agent–related changes in signal intensity in T2-weighted images.

RESULTS Analysis of T1-weighted images revealed that mean ± SD time to maximal enhancement after gadoxetic acid injection was 10.5 ± 3.99 minutes. Signal intensity of T2-weighted images was not significantly affected by gadoxetic acid administration. No injection-related adverse effects were observed in any dog.

CONCLUSIONS AND CLINICAL RELEVANCE Results indicated that gadoxetic acid can be used for hepatic MRI in healthy dogs and the resultant hepatic enhancement patterns are similar to those described for humans. Maximal contrast enhancement occurred between 10 and 15 minutes after contrast agent injection; thus, T2-weighted images may be obtained in the interval between injection and maximal enhancement for a more time-efficient clinical protocol.

Abstract

OBJECTIVE To determine, by means of MRI, the time to maximal contrast enhancement in T1-weighted images following IV administration of gadoxetic acid in healthy dogs and assess the impact of gadoxetic acid on the signal intensity of T2-weighted images.

ANIMALS 7 healthy dogs.

PROCEDURES No hepatic abnormalities were detected during ultrasonographic examination. Each dog was anesthetized and positioned in dorsal recumbency for MRI. Transverse T1- and T2-weighted images of the liver were acquired prior to and following (at 5-minute intervals) IV injection of 0.1 mL of gadoxetic acid/kg. Signal intensity of the liver parenchyma was measured in 3 regions of interest in the T1- and T2-weighted images before and at various times point after contrast agent administration. Time versus signal-to-noise ratio curves were plotted to determine time to maximal contrast enhancement and contrast agent–related changes in signal intensity in T2-weighted images.

RESULTS Analysis of T1-weighted images revealed that mean ± SD time to maximal enhancement after gadoxetic acid injection was 10.5 ± 3.99 minutes. Signal intensity of T2-weighted images was not significantly affected by gadoxetic acid administration. No injection-related adverse effects were observed in any dog.

CONCLUSIONS AND CLINICAL RELEVANCE Results indicated that gadoxetic acid can be used for hepatic MRI in healthy dogs and the resultant hepatic enhancement patterns are similar to those described for humans. Maximal contrast enhancement occurred between 10 and 15 minutes after contrast agent injection; thus, T2-weighted images may be obtained in the interval between injection and maximal enhancement for a more time-efficient clinical protocol.

All Time Past Year Past 30 Days
Abstract Views 30 0 0
Full Text Views 1428 1131 84
PDF Downloads 229 136 10
Advertisement